Primary Objectives:
- Examine the impact of SIGNATERA on adjuvant treatment decisions
- Determine the rate of recurrence of patients diagnosed with CRC while asymptomatic using SIGNATERA
Secondary objectives:
- Molecular residual disease clearance as assessed by SIGNATERA
- Percent of patients undergoing surgery for oligometastatic recurrence
- Survival in patients treated with adjuvant versus no adjuvant chemotherapy in patients with SIGNATERA negative test results
- Overall survival
- Impact of SIGNATERA test results on patient quality of life
How understandable was the trial content above?
Hard to understand
Easy to understand
